Yeast susceptibility isolated from blood cultures of patients at the National Cardiology Institute Ignacio Chávez;Susceptibilidad de levaduras aisladas de hemocultivos en pacientes del Instituto Nacional de Cardiología Ignacio Chávez

Revista de Investigacion Clinica

Volumn 61, Issue 4, 2009, Pages 294-299

  Hernández Dueñas, Ana María Del Rocío ^a   Vázquez Larios, Ma Del Rosario ^a   Soto Nieto, Gabriel Israel ^a   Rivera Martínez, Eduardo ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Amphotericine B; Candida; Fluconazole; Itraconazole; Voriconazole

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD CULTURE; CANDIDEMIA; CHILD; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; FUNGAL STRAIN; FUNGUS ISOLATION; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; SCHOOL CHILD;

ADOLESCENT; ADULT; ANTIFUNGAL AGENTS; BLOOD; CANDIDA; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 70350163369     PISSN: 00348376     EISSN: 00348376     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Salavert M, Jarque RI, Pemán GJ. Los aspectos epidemioló gicos cambiantes de la candidemia y sus implicaciones clínico terapéuticas. Enferm Infecc Microbiol Clin 2006; 24(Supl. 1): 36-45.
2. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 1989; 149: 2349-2353
3. Edwards JE. Invasive Candida infections. N Engl J Med 1991; 324(15): 1060-1062
4. Lumbreras C, Lizasoain M, Aguado JM. Antifúngicos de uso sistémico. Enferm Infeccc Microbiol Clin 2003; 21(7): 336-380
5. Martinez-Suarez JV, Rodriguez-Tudela JL. Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain. Antimicrob Agents Chemother 1995; 39(7): 1512-1516
6. White TC. Antifungal drug resistance in Candida albicans. ASM News 1998; 63(8): 427-433
7. Galgiani J. Susceptibility testing of fungi: current status of the standardization process. Antimicrob Agents Chemother 1993; 37(12): 2517-2521 (Pubitemid 23357839)
8. Cantón E, Pemán J, Bosch M, Viudes A, Gobernado M. Actividad del voriconazol sobre levaduras aisladas de hemocultivos determinada por dos métodos. Rev Esp Quimioterap 2005; 18(4): 308-312. (Pubitemid 43294765)
9. Clinical and Laboratory Standard Institute (CLSI). Reference method for broth dilution antifungal susceptibility testing of yeast; approved Standard. 2nd Ed. M27-A2. 2002 Vol22 Number 15. Villanova, PA
10. Clinical and Laboratory Standard Institute (CLSI). Method for antifungal disk diffusion susceptibility testing of yeast; approved guideline M44-A 2002.
11. Etest technical Manual. Edition 2000 AB Biodisk Sweden. Technical Guide 4.
12. Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Yolken RH. Manual of clinical Microbiology. 8th Ed. Editorial ASM Press; 2003, p. 1693-1711
13. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretative breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006; 19: 435-447
14. Torres Rodríguez JM, Madrenys N, Jiménez T, Saballs P. Concentraciones mínimas inhibitorias de levaduras a cinco antifúngicos utilizando un micrométodo de dilución estandarizado y el E-test. Rev Iberoam Micol 1997; 14: 115-118 (Pubitemid 127525790)
15. Durán MT, Velasco D, Canle D, Moure R, Villanueva R. Susceptibilidad antifúngica de aislados de Candida spp. de hemocultivos en un periodo de cinco años (1997-2001). Enferm Infecc Microbiol Clin 2003; 21: 488-492
16. Pfaller MA, Diekeman DJ, Jones RN, Sader HS, Fliut AC, Hollis RJ, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole and voriconazole of isolates collected from 1997 through 1999 in the Sentry Antimicrobial Surveillance Program. J Clin Microbiol 2001; 39(9): 3254-3259
17. Martínez J, Albrecht C. Sensibilidad al fluconazol y a la anfotericina B en cepas de Candida provenientes de aislamientos clínicos. Rev Iberoam Micol 1998; 15: 298-299 (Pubitemid 128533581)
18. Pelletier R, Loranger L, Marcotte H, De Carolis E. Voriconazole and fluconazole susceptibility of Candida isolates. J Med Microbiol 2002; 51: 479-483 (Pubitemid 34492975)
19. Magill SS, Shields C, Sears C, Choti M, Merz WG. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006; 44(2): 529-535 (Pubitemid 43222248)
20. Cornejo JL, Velásquez AC, Diás GA, Volkow FP. Tendencia del perfil de sensibilidad antimicrobiana de los aislamientos de sangre en un hospital oncológico (1998-2003). Salud Pública Mex 2005; 47(4): 288-293
21. Ramírez AML, Perez Miravete A, Santos Preciado JI. Biological features and experimental pathogenicity of Candida strains isolated by hemoculture at the Hospital Infantil de México Federico Gómez. Rev Latinoam Microbiol 1992; 34(4): 259-265
22. Cuenca-Estrella M, Rodríguez D, Almirante B, Morgan J, Planes AM, Almela M, et al. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: result from a population-based active surveillance programme, Barcelona, Spain, 2002-2003. J Antimicrob Chemother 2005; 55(2): 194-199
23. Arcaya NM, Mila L, Pineda MR, Beltran H, Calvo BM. Perfil de sensibilidad antifungica de especies de Candida aisladas de hemocultivos en un hospital universitario, Maracaibo, Venezuela. Rev Iberoam Micol 2006; 23: 97-100.
24. Gallego Luque CP, De la Torre J. Actualización diagnóstica y terapéutica en infecciones fúngicas invasoras: de los antiguos topicos a las nuevas evidencias. Farmacia Hospitalaria 2001; 25(5): 345-355